SEC Tracker
Get the app
FATE · XBRL financial data

Fate Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (FATE's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers22*2732*2221*12
Research and development3432*32353534*29272625*2524
General and administrative1918*21172115*14111111*109
Total operating expenses5350*53525564*43393636*3433
Operating income (loss)(51)(48)*(51)(45)(52)(62)*(41)(37)(35)(35)*(33)(31)
Interest income54*4544*3332*22
Other income (expense)64*37510*4322*21
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(45)(44)*(48)(38)(48)(52)*(38)(34)(32)(32)*(31)(30)
Earnings per share, basic USD per share(0.46)(0.45)*(0.47)(0.33)(0.40)(0.44)*(0.32)(0.29)(0.27)(0.27)*(0.26)(0.25)
Earnings per share, diluted USD per share(0.46)(0.45)*(0.47)(0.33)(0.40)(0.44)*(0.32)(0.29)(0.27)(0.27)*(0.26)(0.25)
Weighted average shares, basic millions of shares9999*101117118118*118119119119*120120
Weighted average shares, diluted millions of shares9999*101117118118*118119119119*120120

Balance sheet

CSV

Fiscal quarters (FATE's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents3342121373836454141474032
Short-term investments—273—268259243196182175157135121
Accounts receivable221144211111
Prepaid and other current assets1315101399565443
Total current assets364332394319310292248230221209180158
Property and equipment, net1029792888264636159575452
Right-of-use asset636261605847454442424141
Total assets544506570529495441399372344319285260
Accounts payable657569444333
Accrued liabilities292832232421171818201415
Total current liabilities413945353739282928363133
Lease liability, non-current999796949278777674737271
Accumulated deficit(1,168)(1,212)(1,260)(1,298)(1,346)(1,398)(1,436)(1,470)(1,502)(1,534)(1,566)(1,596)
Total stockholders' equity403368426397362319288261234207180153
Total liabilities and equity544506570529495441399372344319285260
Common shares outstanding (cover page) millions of shares9999114114114115115115115116117120

Cash flows

CSV

Fiscal quarters (FATE's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(45)(44)*(48)(38)(48)(52)*(38)(34)(32)(32)*(31)(30)
Depreciation and amortization5*5*55*5*5*33*3*3*33*
Net cash from operating activities(38)*(37)*(33)(32)*(29)*(28)*(34)(25)*(24)*(23)*(31)(23)
Purchases of property and equipment1*0*00*0*0*11*2*1*00*
Net cash from investing activities25*45*17(53)*25*23*4320*21*28*2415*
Proceeds from issuing common stock——75(0)————————
Net cash from financing activities0*(0)*951*0*3*01*2*2*——
Net change in cash(13)*9*79(84)*(4)*(2)*9(4)*(1)*6*(7)(7)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Fate Therapeutics322.1(23)119.8M6.6 quarters 10-QJun 30, 2026
Protalix BioTherapeutics2720(10)*80.6M2.6 quarters 10-QJun 30, 2026
Caribou Biosciences261.5(23)*107.2M4.9 quarters 10-QJun 30, 2026
Protara Therapeutics17not reported(15)*59.1M9.3 quarters 10-QJun 30, 2026
TuHURA Biosciences1not reported(8.6)*63.7M0.1 quarters 10-QJun 30, 2026
Alector603.3(34)*111.7M5.1 quarters 10-QJun 30, 2026
Enanta Pharmaceuticals3314(10)*29.1M19.0 quarters 10-QJun 30, 2026
Galectin Therapeutics13not reported(2.4)*100.8M5.4 quarters 10-QJun 30, 2026
Cartesian Therapeutics1480(21)*30.3M7.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.